Viewing Study NCT06607692

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:28 PM
Ignite Modification Date: 2025-12-26 @ 12:00 PM
Study NCT ID: NCT06607692
Status: RECRUITING
Last Update Posted: 2024-10-21
First Post: 2024-09-04
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Sponsor: Fundación de investigación HM
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Solid Tumor Cancer View
None Medulloblastoma View
None High Risk Neuroblastoma View
None High Grade Gliomas View
None Meningioma View
None Paraganglioma View
None Pheochromocytoma View
None Neuroendocrine Tumours (NET) View
None Adrenal Tumours View
Keywords:

Keywords

Keyword Brief Keyword Text View
None solid tumours View
None somatostatin receptors View
None SSTR View